Evotec, Halozyme

Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec (EVO). Investors appear to be unenthusiastic about a potential deal with the reaction in Halozyme shares.
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.
Germany’s Evotec Gets Takeover Interest From Halozyme
Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German drug developer at €2 billion ($2.1 billion). Most Read from BloombergUnder Trump,
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.
Halozyme interested in acquiring Evotec for $2.1B, Bloomberg says
Evotec (EVO) is attracting potential takeover interest from Halozyme Therapeutics (HALO), Eyk Henning of Bloomberg reports, citing people
Halozyme Therapeutics Bids to Acquire German Competitor Evotec
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share,
Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's management and supervisory board to buy the company for 11 euros a share in cash,
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities
FierceBiotech18h
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
BioPharma Dive9h
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
Halozyme’s Strategic Acquisition of Evotec: A Buy Rating for Future Growth and Profitability
Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...
ENDPOINTS NEWS12h
Evotec gains on Halozyme's takeover pro­pos­al
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...
JPMorgan thinks may take time for market to digest Halozyme bid for Evotec
After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR ...
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to ...